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Abstract
The indications for endoscopic papillectomy (EP) are as follows: (1) no inﬁltration of tumor into the bile duct or pancreatic
duct; (2) adenoma or cancer conﬁned to the mucosa; (3) no distant metastasis. EP is performed with a duodenoscope by
snaring with a snare, 15–25 mm in size, from the cephalic to the caudal side. Without local injection into the submucosal
layer, EP is performed using the 120 W, Endocuts mode, followed by bile and pancreatic ducts stenting after the
performance of biliary/pancreatic sphincterotomy. Argon plasma coagulation was used for hemostasis. This article is part of
an expert video encyclopedia.
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Video Related to this Article
Technique
Endoscopic retrograde cholangiopancreatography (ERCP).
Materials
• Endoscope: JF-260V, TJF-260V; Olympus Medical Systems
Corp., Tokyo, Japan.
• Snare: Snare Master; Olympus Medical Systems.
• Guidewire:




; Olympus Medical Systems.
• Sphincterotome: Clever Cut
TM
; Olympus Medical Systems.
• Pancreatic duct stent: Pit-stent
TM
; Gadelius Medical Corp.,
Tokyo, Japan.
• Biliary stent: 7 Fr pigtail stent; Gadelius Medical.
• Hemostasis: APC probe; ERBE Corp., Tu¨bingen, Germany.
• Altoshooter Kaigen Co., Ltd, Osaka, Japan.
• High-frequency electrical current generator: ICC 200 ERBE.
Background
The widespread use of esophagogastroduodenoscopy (EGD)
and extracorporeal ultrasonography (US) has contributed to
the detection of ampullary neoplasms. Surgical resection,
represented by the Whipple procedure, has long been the
standard treatment for ampullary neoplasms. Recent studies
have demonstrated the possibility of endoscopic papillectomy
(EP) as an alternative to surgery for selected patients with
ampullary neoplasms.1–14
Endoscopic Resection of Ampullary Neoplasm
Since the introduction of EP for ampullary adenoma in 1983
by Suzuki et al.,1 and a subsequent report by Binmoeller et al.,2
many cases of ampullary neoplasms treated by EP have been
reported.3–14 Ampullary adenoma without ductal inﬁltration
into the bile and pancreatic duct is considered to be
suitable for EP.
Before endoscopic procedures, all patients receive a
standard premedication consisting of an intravenous ad-
ministration of pentazocine and diazepam or midazolam. EP
is performed with a duodenoscope (JF-260V, TJF-260V;
Olympus Medical Systems Corp., Tokyo, Japan) by snaring
with a snare, 15–25 mm in size, from the cephalic to the
caudal side. Without local injection into the submucosal layer,
en-bloc resection of the tumor is attempted. Piecemeal re-
section is applied if necessary. EP is performed using the
120 W, effect 3, Endocuts mode (ICC 200; ERBE Corp.,
Tu¨bingen, Germany), followed by bile duct stenting (7 Fr,
double pigtail; Gadelius Medical Corp., Tokyo, Japan), and
pancreatic duct stenting (Pit-stentTM, 5 Fr single duodenal
pigtail; Gadelius Medical Corp., Tokyo, Japan) after the per-
formance of biliary/pancreatic sphincterotomy. Argon plasma
coagulation (APC), with a power setting of 40 W and a gas
ﬂow of 0.4–0.5 l min1, is performed for hemostasis.
Endoscopic Papillectomy for Ampullary Cancer
Recent studies have demonstrated the possibility of EP as an
alternative to surgery for selected patients with early ampullary
cancer.14–16 Lymphatic permeation or lymph node metastasis
is sometimes observed when a tumor invades into/beyond the
sphincter of Oddi.16 However, neither lymphatic permeation,
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vascular invasion, nor lymph node metastasis is recognized in
patients with ampullary cancer limited to the mucosa.16 Local
resection for such a tumor can be justiﬁed if no ductal inﬁl-
tration into neither the bile duct nor the pancreatic duct is
observed.15 Long-term outcomes of EP are, however, lacking.
Data on further long-term follow-up are awaited.
Patient Care after the Procedure and Histological
Evaluation of the Resected Specimens
Patients continue fasting after the procedure for a minimum
of 24 h with drip infusion of 2000 ml and remain in the
hospital for at least 72 h. All patients receive antibiotics for
1 day. If no complication is documented, oral feeding is
commenced several days after EP and then the patient can be
discharged after the removal of the bile/pancreatic duct stent.
Evaluation of tumor invasion of the sphincter of Oddi
before EP remains challenging even by endoscopic US (EUS)
or intraductal US.17 Moreover, sufﬁcient margin from the
lesion cannot always be obtained by EP. Therefore, when EP is
performed for an ampullary neoplasm, histological evaluation
of the resected specimen is mandatory for evaluation of its
appropriateness. The resected specimen is handled to achieve
detailed examination. Soft thin tubes are inserted into the
pancreatic/bile duct before ﬁxation by formalin to facilitate
recognition of those structures at histological examination.
The resected specimen is cut into slices along the pancreatic/
bile duct and stained with hematoxylin–eosin stain for
histological evaluation. When histological ﬁndings of the re-
sected specimen reveal malignancy, surgical treatment is usu-
ally recommended. Additional endoscopic treatments such as
APC or neodymium–yttrium–aluminum garnet laser photo-
ablation are useful for residual adenoma.
The patients are followed up by duodenoscopy and US or
enhanced computed tomography at 1, 3, 6, 12, 24, and 36
months afterward. If a residual tumor is proven by histological
examination of endoscopic biopsy specimen, additional endo-
scopic treatment with APC or surgical treatment is considered.
Key Learning Points/Tips and Tricks
• Local injection into the submucosal layer before EP is
unnecessary because of the possible difﬁculty in capturing
the entire lesion with a snare after injection, resulting in
possible positive horizontal margins.
• Resect the tumor as deeply as possible to attain a negative
margin at the vertical end.
• Pancreatic/bile duct stenting are recommended for pre-
vention of post-ERCP pancreatitis and cholangitis.
• APC is effective for hemostasis without a risk of
complications.
• Histological evaluation of the resected specimen is
important.
Complications and Risk Factors
Since EP for ampullary neoplasm has a relatively high com-
plication rate compared with other ERCP-related procedures,
endoscopists who perform EP should be aware of the occur-
rence of complications such as bleeding, pancreatitis, and
perforation after the procedure.
Alternatives
Surgical treatment such as the Whipple procedure, which is a
more invasive treatment compared with EP, can be selected in
patients with ampullary neoplasms.
Case Presentation
A 76-year-old man underwent EGD at a nearby hospital dur-
ing a general check-up, which led to detection of a tumor at
the ampulla of Vater. He was referred for further evaluation.
He had no history of familial adenomatous polyposis. US
(a) (b)
Figure 1 ERCP showed no tumor inﬁltration into the pancreatic (a) and bile duct (b).
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ﬁnding was essentially normal. EUS demonstrated a hypo-
echoic mass, measuring 20 mm in size, at the ampulla of Vater.
The tumor echo was limited to the ampulla of Vater, without
invasion into the duodenal muscularis propria layer, or
pancreatic parenchyma. Duodenoscopy revealed a reddish
exposed-type tumor mass at the ampulla of Vater. ERCP
showed no tumor inﬁltration into the pancreatic/bile duct
(Figure 1(a) and (b)). Intraductal US showed a hypoechoic
mass limited to the ampulla of Vater without invasion of the
duodenal muscularis propria layer, pancreatic parenchyma, or
the sphincter of Oddi. Biopsy of the tumor revealed adenoma.
EP was performed after informed consent was obtained
from the patient. With a snare, 25 mm in diameter, without
injection of material into the submucosal layer, EP was per-
formed using the 120 W, effect 3, Endocuts mode. After the
removal of the resected specimen, a guidewire was inserted in
the pancreatic duct followed by pancreatic sphincterotomy.
Biliary sphincterotomy was also performed, and then bile and
pancreatic duct stents were placed in order to prevent the
development of acute cholangitis and pancreatitis. Endoscopic
hemostasis was performed with APC and an Altoshooter
(Kaigen Co., Ltd., Osaka, Japan). There was no hyper-
amylasemia or clinical symptoms suggesting the development
of pancreatitis or bleeding. Oral feeding was commenced 2
days after the procedure without any adverse events. The bile
duct stent was removed 3 days after the procedure.
The tumor, 17 mm in maximum size, appeared white and
was located mainly in the duodenal portion of the papilla of
Vater. Histology of the resected specimen revealed adenoma.
The margin of the resected specimen was free of tumor at both
the horizontal and vertical ends. The patient showed no re-
currence clinically or endoscopically at the follow-up 9
months later.
Scripted Voiceover
Time (min:sec) Voiceover text
0:05–0:20 Insertion of the scope into the second portion of
the duodenum.
0:28–0:35 Spray indigo carmine dye.
0:45–0:55 Attempt to obtain pancreatogram to facilitate PD
cannulation after resection.
0:58–1:04 Pancreatic cannulation was achieved with
difﬁculty.
1:10–1:40 Resect the tumor as deeply as possible to attain a
negative margin at the vertical end.
1:45–1:55 Endoscopic papillectomy is performed using the
120 W, effect 3, Endocuts mode.
2:00–2:45 The resected specimen is removed unless
immediate hemostasis is necessary.
2:52–3:00 Insertion of the scope again.
3:01–3:15 Cleaning of the ulcer with sterilized water in order
to facilitate additional procedures.
3:20–3:35 Pancreatic duct insertion followed by placement
of the guidewire.
3:40–3:55 Argon plasma coagulation (APC) is useful for
hemostasis without a risk of perforation.
4:20–5:10 Pancreatic sphincterotomy is performed.
5:15–5:40 Biliary cannulation followed by biliary
sphincterotomy.
5:55–6:10 A biliary stent is placed.
6:25–6:40 A pancreatic duct stent is placed.
6:45–7:00 Additional hemostasis with APC is performed.
7:15–7:28 Spray hemostatic agents (sodium alginate) with
Alto Shooter on the ulcer.
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